Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index

Rhea-AI Summary

Werewolf Therapeutics will be added to the Russell 2000® Index on June 28, 2021, a significant milestone reflecting its progress in developing cancer therapeutics.

The company is advancing its lead programs, WTX-124 and WTX-330, into clinical trials. The Russell 2000® Index is a key benchmark representing the small-cap segment of the U.S. equity market, used by many institutional investors for index funds.

Approximately $10.6 trillion in assets benchmark against Russell's indexes, underlining the importance of this inclusion for Werewolf Therapeutics.

Positive

• Inclusion in the Russell 2000® Index enhances visibility and credibility among investors.
• Advancements in lead therapeutic programs, WTX-124 and WTX-330, towards clinical trials.

Negative

• None.

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution on June 28, 2021.

“Werewolf’s inclusion in the Russell 2000® index marks an important milestone that reflects the continued progress we are making toward advancing our lead therapeutic programs, WTX-124 and WTX-330, into the clinic,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. “We are pleased to join the Russell Index and look forward to sharing our story with a broader audience of investors."

The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. The index is a subset of the Russell 3000® Index and represents approximately 10 percent of the total market capitalization of that index. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 2000® Index and the Russell indexes reconstitution, visit the FTSE Russell website.

About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

Investor Contact:

Alan Lada
Solebury Trout
617.221.8006
alada@soleburytrout.com   

Media Contact:

Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com    

Company Contact:

Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com 

FAQ

What does Werewolf Therapeutics' inclusion in the Russell 2000® Index mean for investors?

Inclusion in the Russell 2000® Index increases visibility and can attract more institutional investors, potentially boosting stock performance.

When will Werewolf Therapeutics be added to the Russell 2000® Index?

Werewolf Therapeutics will be added to the Russell 2000® Index on June 28, 2021.

What are the lead programs of Werewolf Therapeutics?

The lead programs of Werewolf Therapeutics are WTX-124 and WTX-330, which are being advanced into the clinic for cancer treatment.

How much market capitalization does the Russell 2000® Index represent?

The Russell 2000® Index represents approximately 10 percent of the total market capitalization of the Russell 3000® Index.

What is the significance of the Russell Index for investment strategies?

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.